Invitation to comment on the commercial release of a genetically modified mosquito strain to help prevent dengue outbreaks (DIR 207)

Overview

The Gene Technology Act 2004 was enacted to provide a regulatory framework for the assessment and approval of activities involving genetically modified organisms in Australia, including their import, commercial release, and handling. This legislation was introduced to address the need for a cohesive and comprehensive regulatory system that balances the potential benefits of genetic modification with the protection of human health and the environment. The Act was enacted by the Commonwealth Parliament, reflecting a policy objective to facilitate innovation in biotechnology while ensuring stringent oversight to mitigate any risks associated with genetic modification. The Act establishes the Gene Technology Regulator, who is responsible for assessing applications for the release of genetically modified organisms, including the recently proposed commercial release of genetically modified mosquitoes by Oxitec Australia Pty Ltd. This initiative aims to control the population of Aedes aegypti mosquitoes in Queensland to prevent dengue outbreaks, demonstrating the Act's application in managing public health risks through biotechnology.

Scope and Application

The proposed legislation under DIR 207, concerning the commercial release of genetically modified (GM) mosquitoes by Oxitec Australia Pty Ltd, primarily applies to the entities involved in the genetic modification, importation, and commercial use of these mosquitoes within Queensland. This legislation targets Oxitec Australia and any other entities directly involved in the development, testing, and deployment of the GM mosquitoes, which are engineered to prevent the survival of female offspring and thereby reduce the population of Aedes aegypti mosquitoes. The geographic reach of this legislation is confined to Queensland, focusing on areas where dengue outbreaks pose significant public health risks. The legislation also extends its purview to various government bodies, including the Gene Technology Regulator, Australian Pesticides and Veterinary Medicines Authority, Department of Agriculture, Fisheries and Forestry, and the Department of Climate Change, Energy, the Environment and Water, each of which must provide their respective approvals for the commercial use of these GM mosquitoes. The application process is multifaceted, requiring detailed assessments and clearances from multiple agencies before any commercial release can occur. While the legislation primarily focuses on the prevention of dengue outbreaks through innovative genetic means, it does not explicitly state any exclusions, exemptions, or thresholds. However, the comprehensive risk assessment and risk management plan prepared by the Regulator indicates a stringent evaluation process that will likely encompass various safety and environmental considerations.

Key Provisions

The primary operative sections of the Gazette, specifically DIR 207, concern the assessment of an application by Oxitec Australia Pty Ltd for the commercial release of genetically modified (GM) mosquitoes to control the Aedes aegypti mosquito population in Queensland (Section 1). This application is currently under review by the Gene Technology Regulator. The legislation outlines the necessity for a comprehensive Risk Assessment and Risk Management Plan (RARMP) to be prepared, which includes an invitation for written submissions on human health, safety, and environmental impacts (Section 2). This submission process is critical for the Regulator's decision on whether to grant the necessary licence for the release of these GM mosquitoes. The obligations imposed by this Act on the parties involved are multi-faceted. Firstly, Oxitec Australia Pty Ltd must submit a detailed application that includes the proposed method of controlling the mosquito population and the anticipated environmental and health impacts. The Regulator is mandated to prepare and make available a RARMP, inviting public input to ensure all potential risks and benefits are thoroughly evaluated (Section 3). Additionally, the legislation necessitates that the application undergoes scrutiny not only by the Regulator but also by several other governmental bodies, including the Australian Pesticides and Veterinary Medicines Authority (APVMA), Department of Agriculture, Fisheries and Forestry (DAFF), and Department of Climate Change, Energy and the Environment and Water (DCCEEW) (Section 4). This multi-agency review process ensures that the release of GM mosquitoes meets all regulatory requirements across various sectors. Any breach of the conditions set out in this legislation could lead to significant consequences. While the specific offences, penalties, and consequences are not detailed within the provided text, it is clear that non-compliance could result in the refusal of the application and potential legal action against Oxitec Australia Pty Ltd. The stringent multi-agency review process and public consultation requirement underscore the importance of adhering to the outlined obligations to avoid severe repercussions, including the possibility of civil or criminal penalties, although the exact nature of these penalties is not specified within the given text (Section 5).